Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × utomilumab × 90 days × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1 Breast Neoplasms 1

Interventions

Specimen Handling 269 pembrolizumab 241 Magnetic Resonance Spectroscopy 211 Carboplatin 169 Biopsy 158 Nivolumab 140 Cyclophosphamide 137 Cisplatin 137 Paclitaxel 119 Radiotherapy 105 Gemcitabine 101 Bevacizumab 96 durvalumab 85 venetoclax 81 Dexamethasone 76 Rituximab 75 Oxaliplatin 74 Fluorouracil 69 Prednisone 64 Docetaxel 64 fludarabine 63 atezolizumab 63 Ipilimumab 63 Capecitabine 62 Cytarabine 60 Radiosurgery 59 Radiation 59 olaparib 58 Doxorubicin 58 Etoposide 53

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03971409 2026-04-17

InCITe

University of California, San Francisco

Phase 2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡